{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:41:15Z","timestamp":1792669275088,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"vor","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007301","name":"Harvard University Center for AIDS Research","doi-asserted-by":"publisher","award":["P30 AI060354"],"award-info":[{"award-number":["P30 AI060354"]}],"id":[{"id":"10.13039\/100007301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013915","name":"Sarnoff Cardiovascular Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016369","name":"Kohlberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL130539-01A1"],"award-info":[{"award-number":["1R01HL130539-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL137562-01A1"],"award-info":[{"award-number":["1R01HL137562-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K24HL113128-06"],"award-info":[{"award-number":["K24HL113128-06"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FRN 147814"],"award-info":[{"award-number":["FRN 147814"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["12FTF12060588"],"award-info":[{"award-number":["12FTF12060588"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jacc.2018.02.037","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T14:25:48Z","timestamp":1521469548000},"page":"1755-1764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1468,"title":["Myocarditis in Patients Treated With Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"71","author":[{"given":"Syed S.","family":"Mahmood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Fradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine V.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie M.","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongras","family":"Damrongwatanasuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Kirchberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magid","family":"Awadalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek Z.O.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J.","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarju","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paaladinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Groarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2018.02.037_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"2010","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.02.037_bib2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.02.037_bib3","unstructured":"Approved Drugs - Nivolumab (Dec 22, 2014). Silver Spring, MD: U.S. Food and Drug Administration,\u00a02014."},{"key":"10.1016\/j.jacc.2018.02.037_bib4","unstructured":"Approved Drugs - Pembrolizumab (Sep 4, 2014). Silver Spring, MD: U.S. Food and Drug Administration,\u00a02014."},{"key":"10.1016\/j.jacc.2018.02.037_bib5","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.02.037_bib6","doi-asserted-by":"crossref","first-page":"e003514","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab","volume":"9","author":"Tadokoro","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2018.02.037_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"Laubli","year":"2015","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jacc.2018.02.037_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jacc.2018.02.037_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jacc.2018.02.037_bib10","first-page":"9","article-title":"Treating with checkpoint inhibitors\u2014figure $1 million per patient","volume":"8 Spec Issue","author":"Andrews","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jacc.2018.02.037_bib11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd4476","article-title":"The immune checkpoint inhibitors: where are we now?","volume":"13","author":"Webster","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacc.2018.02.037_bib12","series-title":"Drug Information Handbook: A Clinically Relevant Resource for All Healthcare Professionals","author":"Lexicomp","year":"2017"},{"key":"10.1016\/j.jacc.2018.02.037_bib13","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.02.037_bib14","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","year":"2009"},{"key":"10.1016\/j.jacc.2018.02.037_bib15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.02.037_bib16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jcmg.2014.11.017","article-title":"Late gadolinium enhancement among survivors of sudden cardiac arrest","volume":"8","author":"Neilan","year":"2015","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2018.02.037_bib17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/CIRCULATIONAHA.106.613596","article-title":"Cardiogenic shock: current concepts and improving outcomes","volume":"117","author":"Reynolds","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.02.037_bib18","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jacc.2012.12.014","volume":"61","author":"Epstein","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.02.037_bib19","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.jacc.2013.07.067","article-title":"The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation","volume":"62","author":"Neilan","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.02.037_bib20","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.02.037_bib21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1161\/CIRCULATIONAHA.108.769489","article-title":"Predictors of outcome in patients with suspected myocarditis","volume":"118","author":"Kindermann","year":"2008","journal-title":"Circulation"},{"issue":"34","key":"10.1016\/j.jacc.2018.02.037_bib22","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2018.02.037_bib23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2018.02.037_bib24","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","article-title":"Cardiovascular magnetic resonance in myocarditis: a JACC white paper","volume":"53","author":"Friedrich","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.02.037_bib25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti\u2013programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2018.02.037_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/CMR.0b013e32835c7e68","article-title":"Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma","volume":"23","author":"Bernardo","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jacc.2018.02.037_bib27","article-title":"Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management","author":"Huffman","year":"2017","journal-title":"Am J Clinical Oncol"},{"key":"10.1016\/j.jacc.2018.02.037_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jacc.2018.02.037_bib29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.117.026386","article-title":"Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis","volume":"136","author":"Ammirati","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.02.037_bib30","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.jacc.2017.08.050","article-title":"Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis","volume":"70","author":"Gr\u00e4ni","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.02.037_bib31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJMc1615251","article-title":"Myocarditis with immune checkpoint blockade","volume":"376","author":"Ederhy","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.02.037_bib32","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jacc.2018.02.037_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718333680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718333680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T02:50:13Z","timestamp":1656730213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109718333680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":33,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0735109718333680"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732892315.793555467","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}